![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Groupe Francais De Pneumo-Cancerologie Sanofi-Synthelabo Chugai Pharma USA |
---|---|
Information provided by: | Groupe Francais De Pneumo-Cancerologie |
ClinicalTrials.gov Identifier: | NCT00418704 |
The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.
Condition | Intervention | Phase |
---|---|---|
Non Small Cell Lung Cancer |
Drug: Erlotinib Drug: taxotere |
Phase II |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression. |
Estimated Enrollment: | 100 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | January 2009 |
A multicenter phase II trial , prospective, randomized, open, non comparative
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients with non small-cell lung cancer stage IV and IIIB (T4 with pleural effusion) in elderly independent patients évaluant
Inclusion Criteria:
Exclusion Criteria:
Contact: Hervé LECAER, Professor | +33 94 60 51 10 | herve.lecaer@ch-draguignan.fr |
France | |
Hospital Draguignan | Recruiting |
DRAGUIGNAN, France, 83300 | |
Contact: Hervé LECAER, Professor +33 4 94 60 51 10 herve.lecaer@ch-draguignan.fr | |
Principal Investigator: Christos CHOUAID, Professor | |
Hôpital du Cluzeau | Recruiting |
LIMOGES, France | |
Contact: Alain VERGNENEGRE, Professor +33 5 55 05 66 29 avergne@unilim.fr | |
Principal Investigator: Alain VERGNENEGRE, Professor |
Principal Investigator: | Hervé LECAER, Professor | Groupe Francais De Pneumo-Cancerologie |
Responsible Party: | GFPC ( Dr LECAER Hervé ) |
Study ID Numbers: | GFPC 05-04 |
Study First Received: | January 4, 2007 |
Last Updated: | May 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00418704 |
Health Authority: | France: Institutional Ethical Committee |
cancer Lung cancer None small-cell lung cancer |
Erlotinib Thoracic Neoplasms Non-small cell lung cancer Disease Progression Carcinoma Carcinoma, Small Cell Docetaxel |
Pleural Effusion Respiratory Tract Diseases Lung Neoplasms Lung Diseases Gemcitabine Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |